logo

For the Inventor, By the Inventor

Malden, Netherlands

Johan W Scheeren

USPTO Granted Patents = 9

Average Co-Inventor Count = 3.6

ph-index = 4

Forward Citations = 54(Granted Patents)


Location History:

  • Nijmegen, NL (1998)
  • Malden, NL (1992 - 2002)

Company Filing History:

goldMedal9 out of 25 
 
Pharmachemie B.v.
 patents

Years Active: 1992-2002

Loading Chart...
9 patents (USPTO):Explore Patents
1. 6344571 - Water soluble analogs and prodrugs of paclitaxel (2002-02-05),
2. 5874595 - Method for the preparation of baccatin III and derivatives thereof from (1999-02-23),
3. 5874550 - Process for preparing epirubicin or acid addition salts thereof from (1999-02-23),
4. 5760072 - Paclitaxel prodrugs, method for preparation as well as their use in (1998-06-02),
5. 5710135 - Anthracycline prodrugs, method for preparation as well as their use in (1998-01-20),
6. 5294701 - Anthracycline compounds and intermediates (1994-03-15),
7. 5183913 - Cyclic triketone compounds and trimethylsilyoxy butadiene compounds and (1993-02-02),
8. 5097051 - Cyclic triketone compounds and trimethylsilyloxy butadiene compounds and (1992-03-17),
9. 5079349 - Trimethylsilyl acetylene compounds, their preparation and their use in (1992-01-07),

Title: **Innovator Spotlight: Johan W. Scheeren**

Introduction

Johan W. Scheeren is a talented inventor based in Malden, Netherlands, known for his significant contributions to the field of pharmaceuticals. With a remarkable portfolio of nine patents, he focuses on advancing cancer treatment through innovative drug formulations.

Latest Patents

One of Johan's notable patents is for "Water soluble analogs and prodrugs of paclitaxel." This invention presents water-soluble antitumor analogs of paclitaxel, providing a pharmaceutical composition that includes an antineoplastic effective amount of such analogs. Additionally, he has developed a process for preparing epirubicin or its acid addition salts from daunorubicin. This method improves upon prior art by allowing the synthesis of epirubicin without the disadvantages found in previous methods, thereby enhancing efficiency in pharmaceutical production.

Career Highlights

Johan W. Scheeren's career is marked by his commitment to pharmaceutical innovation. Working with Pharmachemie B.V., he has focused on the development of new methods to enhance drug solubility and efficacy. His work continues to contribute to better treatment options for patients facing cancer.

Collaborations

Collaboration has been vital to Johan's work, with significant contributions from his colleagues Dick De Vos and Dirk De Vos. Together, they have worked on various projects aimed at improving the efficiency of drug formulations and responses in oncological therapies.

Conclusion

In summary, Johan W. Scheeren stands out as a key figure in pharmaceutical innovation. His extensive patent portfolio and collaborative efforts underscore his dedication to improving cancer treatments. Through his inventions, he has made a profound impact on the medical field, showcasing the importance of innovation in tackling complex health challenges.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…